Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07134556) titled 'Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC' on Aug. 6.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: MedSIR

Condition: Triple Negative Breast Cancer PDL-1 Positive

Intervention: Drug: Zimberelimab (AB122) Drug: Domvanalimab (DOM)

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: December 8, 2025

Target Sample Size: 25

To k...